Anthem Biosciences Ltd Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated May 14, 2026 3 min read

Anthem Biosciences faces a pivotal Q4 as it navigates the cyclical nature of its CDMO business and the integration of significant new capacity. Investors will be looking for signs of a strong finish to FY26, specifically regarding margin resilience and the ramp-up status of its newer production units.

Quick Details

Results date	May 19, 2026
Quarter	Q4 FY 2025-2026
Previous quarter revenue	Rs. 423 Crore
Previous quarter PAT	Rs. 93 Crore
Previous quarter EBITDA margin	41.8%
Market cap	Rs. 45,872.31 Cr
CMP	Rs. 816.65

Anthem Biosciences Ltd Q4 Results Date and Time

The board of directors is scheduled to meet on May 19, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, and to consider the recommendation of a final dividend for FY26.

An earnings conference call is scheduled for May 20, 2026, at 11:00 AM IST to discuss the audited financial results, featuring Mr. Ajay Bhardwaj (MD & CEO) and Mr. Gawir Baig (CFO).

What to expect from Anthem Biosciences Ltd's Q4 FY26 results

In its most recently reported quarter, Anthem Biosciences posted revenue of Rs. 423 Crore, PAT of Rs. 93 Crore, and an EBITDA margin of 41.8%. Management anticipates reaching mid-teens revenue growth of approximately 15% to 16% for the full fiscal year, supported by robust demand in its CRDMO segment which contributes 85-86% of total revenue. The company maintains its guidance for EBITDA and PAT margin growth of 20% plus, underpinned by structural improvements including full backward integration and operational leverage. While Q3 revenue faced headwinds from customer destocking, the company is focusing on the ramp-up of Unit-3 and the construction of the Rs. 1,000 Crore Unit-4 greenfield project to support long-term growth.

Key Things To Watch

Performance vs Guidance Tracking

Revenue growth — 15-16% for FY26 — 11.2% YoY achieved in 9M
EBITDA margin growth — 20%+ for FY26 — 22.6% YoY achieved in 9M
PAT margin growth — 20%+ for FY26 — 9.1% YoY achieved in 9M
Unit-IV commissioning — FY27-28 — Construction started

Strategic execution and capex

Unit-III fermentation block commissioning expected by end of FY26
Unit-IV greenfield project targeting ~400 KL custom synthesis and ~100 KL fermentation capacity
16 KL peptide facility investment of approximately Rs. 200 Crore

Operating metric trajectory

Commercial molecules count currently at 14, up from 10 at IPO
Unit-2 (376 KL) occupancy at ~75% on existing 300 KL capacity
Employee cost as a percentage of sales sustaining at approximately 12.5%

Risks and headwinds to monitor

Customer destocking impact on Q4 volumes
Business lumpiness inherent to the CDMO model
Monitoring finalization of rules for new Labour Codes following the Rs. 25.4 Crore Q3 provision

Frequently Asked Questions

When will Anthem Biosciences announce Q4 FY 2025-2026 results?

Anthem Biosciences is scheduled to announce its Q4 FY 2025-2026 results on May 19, 2026.

Will Anthem Biosciences announce a dividend with these results?

Yes, the board meeting on May 19, 2026, includes an agenda item to consider the recommendation of a final dividend for FY26.

What was Anthem Biosciences' revenue in its previous quarter?

Anthem Biosciences reported consolidated revenue from operations of Rs. 423 Crore in Q3 FY26.

When does the company expect the Unit-IV expansion to be commissioned?

Management is targeting the commissioning of the Unit-IV greenfield project within two years, aiming for completion in FY27-28.

Is Anthem Biosciences on track with its previously stated revenue growth guidance?

The company reported 11.2% YoY revenue growth for 9MFY26 and is aiming for 15-16% growth for the full fiscal year. Management noted that Q4 performance will be critical to meeting this full-year target.